ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca, LG Chem and Boryung Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

AstraZeneca×LG Chem×Boryung Pharmaceutical×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZenecaLG ChemBoryung Pharmaceutical
studies on the registry4,197184143
open to participants now2981023
phase 3 studies under way20031
reach primary completion within a year16827
programswith a study of their own in two years119+5 named only1018

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZenecaLG ChemBoryung Pharmaceutical
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

LG Chem: 2 of its 10 programs at phase 1

  1. Reference Drug (Eutropin, 4 IU/vial)phase 1
  2. Test Drug (Eutropin Catridge, 48IU/Cartridge)phase 1
20%

Boryung Pharmaceutical: 8 of its 18 programs at phase 1

  1. BR1015phase 1
  2. dapagliflozinphase 1
  3. Metforminphase 1
  4. BR2021phase 1
  5. olaparibphase 1

and 3 more — sign in to see them all

44%
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

LG Chem: 1 of its 10 programs at phase 2

  1. LG00313112phase 2
10%

Boryung Pharmaceutical: 9 of its 18 programs at phase 2

  1. bosmolisibphase 2
  2. BR1400-1phase 2
  3. BR1400-2phase 2
  4. BR1400-3phase 2
  5. BR1400phase 2

and 4 more — sign in to see them all

50%
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

LG Chem: 4 of its 10 programs at phase 3

  1. rilogrotugphase 3
  2. LBVDphase 3
  3. Metforminphase 3
  4. dapagliflozinphase 3
40%

Boryung Pharmaceutical: 1 of its 18 programs at phase 3

  1. Pioglitazonephase 3
6%
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

LG Chem: 3 of its 10 programs at approved, new studies

  1. Fang Le Shu (Follitrope)approved, new study
  2. Leuprolideapproved, new study
  3. gemigliptinapproved, new study
30%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca61 readouts · 16 phase 3

AstraZeneca, Nov ’26: 6 programs whose next study reaches primary completion

  1. elecoglipronphase 3 · Nov 18 · NCT07723833
  2. Elecoglipron Test formulation 1 Dose Aphase 1 · Nov 18 · NCT07723833
  3. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  4. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  5. durvalumabapproved, new study · Nov 30 · NCT07081633

and 1 more — sign in to see them all

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 12 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 7 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
LG Chem0 readouts · 0 phase 3············
Boryung Pharmaceutical9 readouts · 0 phase 3···

Boryung Pharmaceutical, Feb ’27: 5 programs whose next study reaches primary completion

  1. BR1400phase 2 · Feb 1 · NCT07373613
  2. BR1400-1phase 2 · Feb 1 · NCT07373613
  3. BR1400-2phase 2 · Feb 1 · NCT07373613
  4. BR1400-3phase 2 · Feb 1 · NCT07373613
  5. BR1400-4phase 2 · Feb 1 · NCT07373613
··

Boryung Pharmaceutical, May ’27: 3 programs whose next study reaches primary completion

  1. BR5402Aphase 2 · May 0 · NCT06821945
  2. BR5402Bphase 2 · May 0 · NCT06821945
  3. BR5402D-1phase 2 · May 0 · NCT06821945
···

Boryung Pharmaceutical, Sep ’27: 1 program whose next study reaches primary completion

  1. bosmolisibphase 2 · Sep 0 · NCT07180771
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

LG Chem

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 1

Boryung Pharmaceutical

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 17 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionAstraZenecaLG ChemBoryung Pharmaceutical
Prostatic Neoplasmsall three · compare here

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

LG Chem in Prostatic Neoplasms: 1 program

  1. Leuprolideapproved, new study

Their studies: LG Chem’s studies of Prostatic Neoplasms in search

Boryung Pharmaceutical in Prostatic Neoplasms: 1 program

  1. olaparibphase 1

Their studies: Boryung Pharmaceutical’s studies of Prostatic Neoplasms in search

Diabetes Mellitus, Type 2all three · compare here

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

LG Chem in Diabetes Mellitus, Type 2: 3 programs

  1. Metforminphase 3
  2. dapagliflozinphase 3
  3. gemigliptinapproved, new study

Their studies: LG Chem’s studies of Diabetes Mellitus, Type 2 in search

Boryung Pharmaceutical in Diabetes Mellitus, Type 2: 5 programs

  1. Pioglitazonephase 3
  2. dapagliflozinphase 1
  3. Metforminphase 1
  4. BR3006phase 1
  5. BR3409phase 1

Their studies: Boryung Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Breast Neoplasmsall three · compare here

AstraZeneca in Breast Neoplasms: 9 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 4 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

LG Chem in Breast Neoplasms: 1 program

  1. Leuprolideapproved, new study

Their studies: LG Chem’s studies of Breast Neoplasms in search

Boryung Pharmaceutical in Breast Neoplasms: 1 program

  1. olaparibphase 1

Their studies: Boryung Pharmaceutical’s studies of Breast Neoplasms in search

Renal Insufficiency, Chronicall three · compare here

AstraZeneca in Renal Insufficiency, Chronic: 8 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. Berzanoflastphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency, Chronic in search

LG Chem in Renal Insufficiency, Chronic: 1 program

  1. dapagliflozinphase 3

Their studies: LG Chem’s studies of Renal Insufficiency, Chronic in search

Boryung Pharmaceutical in Renal Insufficiency, Chronic: 1 program

  1. dapagliflozinphase 1

Their studies: Boryung Pharmaceutical’s studies of Renal Insufficiency, Chronic in search

Heart Failureall three · compare here

AstraZeneca in Heart Failure: 6 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. balcinrenonephase 3
  4. Pexerelgonphase 2
  5. dapagliflozinapproved, new study

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Heart Failure in search

LG Chem in Heart Failure: 1 program

  1. dapagliflozinphase 3

Their studies: LG Chem’s studies of Heart Failure in search

Boryung Pharmaceutical in Heart Failure: 1 program

  1. dapagliflozinphase 1

Their studies: Boryung Pharmaceutical’s studies of Heart Failure in search

Diabetes Mellitusall three · compare here

AstraZeneca in Diabetes Mellitus: 1 program

  1. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus in search

LG Chem in Diabetes Mellitus: 2 programs

  1. Metforminphase 3
  2. dapagliflozinphase 3

Their studies: LG Chem’s studies of Diabetes Mellitus in search

Boryung Pharmaceutical in Diabetes Mellitus: 3 programs

  1. Pioglitazonephase 3
  2. dapagliflozinphase 1
  3. Metforminphase 1

Their studies: Boryung Pharmaceutical’s studies of Diabetes Mellitus in search

Obesityall three · compare here

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

LG Chem in Obesity: 1 program

  1. Metforminphase 3

Their studies: LG Chem’s studies of Obesity in search

Boryung Pharmaceutical in Obesity: 1 program

  1. Metforminphase 1

Their studies: Boryung Pharmaceutical’s studies of Obesity in search

Ovarian Neoplasmsall three · compare here

AstraZeneca in Ovarian Neoplasms: 2 programs

  1. saruparibphase 3
  2. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Ovarian Neoplasms in search

LG Chem in Ovarian Neoplasms: 1 program

  1. LG00313112phase 2

Their studies: LG Chem’s studies of Ovarian Neoplasms in search

Boryung Pharmaceutical in Ovarian Neoplasms: 1 program

  1. olaparibphase 1

Their studies: Boryung Pharmaceutical’s studies of Ovarian Neoplasms in search

Diabetes Mellitus, Type 1all three · compare here

AstraZeneca in Diabetes Mellitus, Type 1: 1 program

  1. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 1 in search

LG Chem in Diabetes Mellitus, Type 1: 1 program

  1. dapagliflozinphase 3

Their studies: LG Chem’s studies of Diabetes Mellitus, Type 1 in search

Boryung Pharmaceutical in Diabetes Mellitus, Type 1: 1 program

  1. dapagliflozinphase 1

Their studies: Boryung Pharmaceutical’s studies of Diabetes Mellitus, Type 1 in search

Fastingall three · compare here

AstraZeneca in Fasting: 1 program

  1. balcinrenonephase 3

Their studies: AstraZeneca’s studies of Fasting in search

LG Chem in Fasting: 1 program

  1. Metforminphase 3

Their studies: LG Chem’s studies of Fasting in search

Boryung Pharmaceutical in Fasting: 1 program

  1. Metforminphase 1

Their studies: Boryung Pharmaceutical’s studies of Fasting in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 18 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 13 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

–

Boryung Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 1 program

  1. olaparibphase 1

Their studies: Boryung Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Renal Insufficiency2 of 3 · compare here

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

LG Chem in Renal Insufficiency: 1 program

  1. gemigliptinapproved, new study

Their studies: LG Chem’s studies of Renal Insufficiency in search

–

Show all 17

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetAstraZenecaLG ChemBoryung Pharmaceutical
SLC5A2dapagliflozindapagliflozindapagliflozin
PARP1palacaparib, saruparibrule–olaparibrule
COXFA4–MetforminruleMetforminrule
COXFA4L2–MetforminruleMetforminrule
GPD2–MetforminruleMetforminrule
MT-ND1–MetforminruleMetforminrule
MT-ND2–MetforminruleMetforminrule
MT-ND3–MetforminruleMetforminrule
MT-ND4–MetforminruleMetforminrule
MT-ND4L–MetforminruleMetforminrule
MT-ND5–MetforminruleMetforminrule
MT-ND6–MetforminruleMetforminrule
NDUFA1–MetforminruleMetforminrule
NDUFA10–MetforminruleMetforminrule
NDUFA11–MetforminruleMetforminrule
NDUFA12–MetforminruleMetforminrule
NDUFA13–MetforminruleMetforminrule
NDUFA2–MetforminruleMetforminrule
NDUFA3–MetforminruleMetforminrule
NDUFA5–MetforminruleMetforminrule
NDUFA6–MetforminruleMetforminrule
NDUFA7–MetforminruleMetforminrule
NDUFA8–MetforminruleMetforminrule
NDUFA9–MetforminruleMetforminrule
NDUFAB1–MetforminruleMetforminrule
NDUFAF1–MetforminruleMetforminrule
NDUFAF2–MetforminruleMetforminrule
NDUFAF3–MetforminruleMetforminrule
NDUFAF4–MetforminruleMetforminrule
NDUFB1–MetforminruleMetforminrule
NDUFB10–MetforminruleMetforminrule
NDUFB11–MetforminruleMetforminrule
NDUFB2–MetforminruleMetforminrule
NDUFB3–MetforminruleMetforminrule
NDUFB4–MetforminruleMetforminrule
NDUFB5–MetforminruleMetforminrule
NDUFB6–MetforminruleMetforminrule
NDUFB7–MetforminruleMetforminrule
NDUFB8–MetforminruleMetforminrule
NDUFB9–MetforminruleMetforminrule
NDUFC1–MetforminruleMetforminrule
NDUFC2–MetforminruleMetforminrule
NDUFS1–MetforminruleMetforminrule
NDUFS2–MetforminruleMetforminrule
NDUFS3–MetforminruleMetforminrule
NDUFS4–MetforminruleMetforminrule
NDUFS5–MetforminruleMetforminrule
NDUFS6–MetforminruleMetforminrule
NDUFS7–MetforminruleMetforminrule
NDUFS8–MetforminruleMetforminrule
NDUFV1–MetforminruleMetforminrule
NDUFV2–MetforminruleMetforminrule
NDUFV3–MetforminruleMetforminrule
PARP2saruparibrule–olaparibrule
A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · LG Chem 5 of 10 · Boryung Pharmaceutical 5 of 18 programs (37 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).